description="lightestColor"> href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=37&F=H"> src="http://www.shareholdervision.com/guru-email/g/logo-wide.jpg"
border="0" height="77" width="700" />

You are
subscribed as Subscriber

StockGuru Blog:
Vicor Technologies, Inc. (OTCBB: VCRT)

width="223" />

Vicor Technologies, Inc. (OTCBB: VCRT)

LEVEL 1 TRADE IDEA

Dear Members,

Vicor’s PD2i-VS™ Has Been Tested by U.S. Army Institute
of Surgical Research (USAISR)

This represents an amazing opportunity for Vicor.

Determined to minimize mortality rate of battlefield casualties, the
U.S. Army Institute of Surgical Research has been working with
Vicor’s PD2i-VS system through a research collaboration and has
tested it against the best methodologies currently available. In extensive
real-world testing involving several studies with data provided by the
USAISR, the PD2i-VS™ has proven to be more predictive than all other
compared technologies.

In Vicor’s most recent study with Army provided data, the
PD2i-VS™ examined 325 civilian trauma injury victims, twenty of whom
would later die of their injuries. Incredibly, the PD2i-VS™
correctly identified all twenty.

Even more importantly, of the twenty who died, conventional trauma
triaging techniques had selected only six for lifesaving intervention in
the field.

This suggests both that current trauma triage methods are woefully
inadequate, and that the PD2i-VS™ is poised to make an extraordinary
contribution to combat and trauma survival in the near future.

Presentation by USAISR Researcher

Andriy Batchinsky, MD, a USAISR researcher, presented findings from a
study of Vicor’s PD2i VS™ at the American Heart
Association’s Resuscitation Science Symposium 2009 (November 14-15,
2009). Dr. Batchinsky presented “Does Heart-Rate Complexity Analysis
Work in the Real World? Changes in the Point Correlation Dimension of
Heart Rate during Prehospital Lifesaving Interventions.”

This was the first presentation at a major scientific conference
featuring Vicor’s proprietary PD2i™ nonlinear algorithm. The
objective of “Does Heart-Rate Complexity Analysis Work in the Real
World?” was to evaluate the ability of the PD2i VS™ to
distinguish trauma patients receiving lifesaving interventions from those
who did not based on analysis of EKGs from 325 pre-hospital trauma
patients. The PD2i™ nonlinear algorithm value was calculated on both
unedited (raw) and on manually verified, noise-and ectopy-free (clean) EKG
sections. In conclusion, researchers found that analysis of heart rate
complexity using the PD2i™ nonlinear algorithm and software
identifies trauma patients with good sensitivity (low percentage of false
negatives) and that results are similar using either “raw” or
“clean” EKGs. Additional studies of automated trauma triage
using the PD2i VS™ are planned

Additionally, Dr. Batchinsky made the following presentations of the
USAISR’s continuing studies of the PD2i VS™:

“Are We Listening to Music or Noise? Use of the Lyapunov
Exponent for Comprehensive Assessment of Heart Rate Complexity during
Hemorrhage in Sedated Conscious Miniature Swine” 8th International
Conference on Complexity in Acute Illness – August 28-30, 2009
– Palo Alto, CA

“Complexity in Animal Models” and “Continuous
Complexity Analysis and Remote Battlefield Triage” International
Experts of Complexity and Variability at the Bedside Round Table –
August 24-25, 2009 – Wakefield, CA

“Does Heart Rate Complexity Add to Traditional Vital Signs for
Trauma Patient Triage?” ATACCC 2009 Conference – August 10-12,
2009 – St. Petersburg Beach, FL

“Toward Automated Detection of Life-threatening Injury Using
Comprehensive Assessment of the Electrocardiogram” Smart Monitoring
2009 Conference – August 9, 2009 – St. Petersburg Beach,
FL

Peer-Reviewed Medical Journals Indicate the Value the Medical
Community Places on Vicor

While I know most of you will not read the details which follow
what I hope you will take away from this is that VICOR has met with the
strong respect of the medical community.  Vicor has tested is product
in physician’s offices and the ROLL OUT HAS BEGUN of a product that
has been very well vetted.

A manuscript of Vicor’s study, “Comparison of
linear-stochastic and nonlinear deterministic algorithms in the analysis
of 15-minute clinical EKGs to predict risk of arrhythmic death,”
appeared in Therapeutics and Clinical Risk Management (2009-5, 1-12).

The manuscript chronicles the study of 397 patients admitted to three
emergency room departments for chest pain and determined to be at
low-to-high risk of acute myocardial infarction (MI). Fifteen-minute EKGs
were recorded and R-R intervals assessed by three non-linear algorithms
(PD2i™, DFA, and ApEn) and four conventional linear-stochastic
measures (SDNN, MNN, 1/f-Slope, LF/HF). The sensitivity and relative risk
for predicting arrhythmic death was highest at all time-points for the
PD2i™ algorithm.

“New Measures of Heart-Rate Complexity: Effect of Chest Trauma
and Hemorrhage” is in press in the Journal of Trauma. This USAISR
study analyzed the complex beat-to-beat variability present in the
heart-rate time series, which has been proposed as a “new vital
sign.”

The effect of chest trauma and hemorrhagic shock on heart-rate
complexity (HRC) was examined in an animal model. The study concluded that
heart rate complexity may be useful for diagnosis of trauma and
hemorrhagic shock, and for monitoring resuscitation efforts.

University of Rochester/Catalan Institute of Cardiovascular
Sciences

Vicor is working with the University of Rochester and the Catalan
Institute of Cardiovascular Sciences to use the PD2i CA™ to
retrospectively predict sudden cardiac death in the 651 congestive heart
failure patients studied by the Muerte Subita en Insuficiencia Cardiaca
(MUSIC) trial, in which 52 actually died from SCD.
Vicor expects that
the results of this analysis will be sufficient to support FDA 510(k)
clearance for sudden cardiac death in 2010.

University of Mississippi Medical Center

Vicor is collaborating with the University of Mississippi Medical
Center on several trials:

Brain Injury Risk Stratification Trial

The BIRST trial will determine the ability of the PD2i™
nonlinear algorithm to predict mortality in victims of brain trauma.
PD2i™ will also be assessed for its ability to track the clinical
status of neuro-trauma ICU patients.

Brain trauma is a serious public health challenge. In the U.S. over
300,000 sport-related traumatic brain injuries occur annually, and
according to the Brain Trauma Foundation, approximately 52,000 will
die.

Cardiac Arrhythmia Assessment and Safety in Athletes
(CAASA)

Sudden cardiac death is a leading cause of death among student
athletes. The CAASA trial will test the ability of the PD2i CA™ to
identify those at risk.

The CAASA trial will commence at the University of Mississippi, with
follow-on studies at other prestigious universities.

Complexity Analysis Studies of Trauma in the Emergency Department
(CASTED)

Vicor is in discussions with the University of Mississippi Medical
Center Trauma Center to identify a means of transmitting PD2i-VS™
data during Medivac transport of civilian trauma victims.

Complexity Analysis during Blood Donation (CABLD)

In cooperation with the University of Mississippi Medical Center Blood
Bank, the CABLD trial is testing the ability of the PD2i-VS™ to
detect mild-to-moderate blood loss as determined during blood
donations.

Complexity Analysis during Renal Dialysis (CARD) Trial

CARD will test the use of Heart Rate Variability to evaluate the effect
of fluid loss during dialysis.

Massachusetts General Hospital MGH PD2i-VS Trial

In this study, href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1163&F=H"
target="_blank">Massachusetts General Hospital will test the
PD2i-VS™ for real-time href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1162&F=H">mobile
& ICU triage in an extremely demanding emergency medical
environment.

The teaching hospital for Harvard Medical School, MGH is a Level 1
Adult, Pediatric and Burn Trauma Center admitting over 4,000 trauma and
emergency surgery patients annually.

Dr. Alfred Buxton and Heart Rate Variability

Vicor will be working with renowned electrophysiologist, Dr. Alfred
Buxton, on two trials to learn if measuring Heart Rate Variability is
useful in tracking the progress of cardiac patients undergoing various
rehabilitative treatments following ICD implantation.

Dr. Buxton is a Professor of Medicine at Brown Medical School and
Director of the Cardiology Division at Brown Medical School, and Rhode
Island and Miriam hospitals. He is also the Director of Arrhythmia
Services and the Clinical Cardiac Electrophysiology Laboratory at Rhode
Island and Miriam hospitals.

CARE-t Trial

Vicor’s PD2i Analyzer™ will be used to measure Heart Rate
Variability as a means of determining the efficacy of cognitive behavioral
therapy on cardiac patients with ICDs.

CARE-e Trial

Vicor’s PD2i CA™ is being used to determine the ability of
exercise to reduce arrhythmias in cardiac patients with ICDs.

Target Health, Inc.

Target Health, Inc. is working as the Company’s Contract Research
Organization in regulatory matters as strategic advisors and clinical
consultants for meetings with the FDA.

width="76" />The Sudden Cardiac Arrest Association

Vicor supports the work of the Sudden Cardiac Arrest Association. The
SCAA identifies and unites survivors, those at risk of sudden cardiac
arrest, and those interested in advocating for SCAA issues in their
communities and beyond. The Sudden Cardiac Arrest Association and Vicor
share a mission: to prevent loss of life from Sudden Cardiac Arrest.

PD2i VS™ Presentations and Publications 2009 ATACCC Conference
/ Smart Monitoring 2009 Forum

Vicor’s technology was presented in August at the 2009 Advanced
Technology Applications for Combat Casualty Care (ATACCC) conference and
the 2009 Smart Monitoring Forum in St. Petersburg Beach, Florida.

Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of
Surgical Research (USAISR), made two presentations. The first, Toward
Automated Detection of Life-threatening Injury Using Comprehensive
Assessment of the Electrocardiogram, was presented at Smart Monitoring
2009 during the New Vital Signs, Predictive Variables and Indices
panel.

At ATACCC, Dr. Batchinsky presented Does Heart Rate Complexity Add to
Traditional Vital Signs for Trauma Patient Triage? Both presentations
reviewed findings from trials the USAISR has done with Vicor and described
use of the PD2i-VS™ as a new vital sign in trauma triage.

The premier scientific meeting of the Department of Defense, ATACCC
addresses advances in trauma medicine and the unique medical needs of the
war fighter, identifying technologies that can meet increasingly complex
operational issues.

Sponsored by the Resuscitation Research Laboratory of the University
of Texas Medical Branch, Smart Monitoring is a forum on vital sign
monitoring for combat casualty care, facilitating communication between
industry representatives and medical experts from government, academia,
and the private sector.

2008 International Shock Congress

Exploration of Heart-Rate Complexity to Determine the Need for
Lifesaving Intervention in Combat Casualties was also presented by the
U.S. Army in June, 2008 at the International Shock Congress in Cologne,
Germany. The abstract concerned the initial experiment for trial performed
by the U.S.Army on battlefield wounded soldiers utilizing Vicor’s
PD2i™ technology.

PD2i ™Technology. Journal of Critical Care

Exploration of Heart-Rate Complexity to Determine the Need for
Lifesaving Intervention in Combat Casualties was published in the June,
2008 Journal of Critical Care.

The Company’s first collaborative effort with the U.S. Army, this
study involved combat casualties for whom EKG files were analyzed by
several competing methods. Vicor’s PD2i™ technology correctly
identified the need for immediate life-saving intervention.

Reference: Exploration of heart-rate complexity to determine the need
for lifesaving interventions in combat casualties. Journal of Critical
Care 2008 Jun;(Vol. 23, Issue 2, Pages 265-266)

Papers

Therapeutics & Clinical Risk Management

Vicor’s study, Nonlinear Analysis of the Heartbeats in Public
Patient EKGs Using An Automated PD2i™ Algorithm for Risk
Stratification of Arrhythmic Death was published in the April 2006
Therapeutics and Clinical Risk Management. This study demonstrated the
ability of the PD2i CA™ to risk-stratify patients’ risk for
sudden cardiac death and identify those who require ICD’s
(implantable cardioverter defibrillator) and those who do not.

The study enrolled 37 patients and showed the PD2i test to have a
sensitivity of 100% and a specificity of 85%. In other words, Vicor’s
PD2i™ nonlinear algorithm correctly identified every patient who
went on to suffer a cardiac arrest or sudden cardiac death, while only
recommending over-treatment of 15%. Current risk-stratification criteria
results in over-treatment of 76% of cases,1,2 while only identifying a
fraction of “true-positives” — patients who will go on to
experience cardiac arrests or sudden cardiac death.

Risk Stratification for Arrhythmic Death in an Emergency Department
Cohort: A New Method of Non-Linear PD2i Analysis of the EKG

The Company’s study of 918 patients in six emergency departments,
appeared in the August 2008 issue of Therapeutics and Clinical Risk
Management. Vicor’s PD2i® algorithm and software achieved a
sensitivity of 96% and a specificity of 85% with a negative predictive
value of 99%.

Comparison of Linear–Stochastic and Nonlinear Deterministic
Algorithms in the Analysis of 15-Minute Clinical EKGs to Predict Risk of
Arrhythmic Death

Published August 17th in Therapeutics & Clinical Risk
Management.
The paper describes a study in which 397 emergency room
patients presenting with chest pain were evaluated by seven methodologies:
the PD2i™ nonlinear algorithm, DFA, ApEn, SDNN, MNN, 1/f-Slope, and
LF/HF. The study demonstrated that the PD2i™ nonlinear algorithm,
based on a deterministic model, provided superior assessment of Heart Rate
Variability in brief EKGs compared to measures based on either the linear
stochastic model or other nonlinear ones, and thus provides the basis for
a rapid, accurate, and cost-effective stratification of risk of AD among
patients presenting in an Emergency Department.

Journal of Critical Care
Exploration of Heart-Rate
Complexity to Determine the Need for Lifesaving Intervention in Combat
Casualties was published in the June 2008 Journal of Critical Care. The
Company’s first collaborative effort with the U.S. Army, this study
involved combat casualties for whom EKG files were analyzed by several
competing methods. Vicor’s PD2i™ nonlinear algorithm was the
only method that correctly identified the need for immediate life-saving
intervention in all cases.

American Heart Journal
A Reduction in the Correlation
Dimension of Heartbeat Intervals Precedes Imminent Ventricular
Fibrillation in Human Subjects appeared in Elsevier’s American Heart
Journal. In this study, the PD2i™ nonlinear algorithm and software
demonstrated a sensitivity of 100% and a specificity of 83%.

Ongoing Studies
In addition, Vicor is currently involved
in several ongoing studies which will be submitted to appropriate
publications when complete.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
href="mailto:info@vicortech.com">info@vicortech.com

Thank you,

John Pentony

Publisher, StockGuru.com

Introduction

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial
transformative stage for a biotechnology company on the verge of becoming
a viable commercial enterprise.

This biotechnology company is focused on the commercialization of
innovative, non-invasive medical devices and diagnostics using its
patented, proprietary PD2i™ nonlinear algorithm and software which
is:

• Highly accurate
• Provides user friendly data acquisition
• Effective for trauma triage easily deployed in a portable
  monitor
• Provides a simple noninvasive test for identifying patients at risk of
  sudden cardiac death
• Provides a simple noninvasive test for identifying patients with
  Diabetic Autonomic Neuropathy

width="127" />The PD2i Algorithm and software risk stratifies target
populations to predict future pathological events. As a predictor of
sudden cardiac death it has been shown to be highly accurate, with a
sensitivity approaching 100% and a specificity of ~86%.

The advantage of the PD2i™ nonlinear algorithm is that it
typically uses recordings made at rest and does not require stress-testing
or any active participation from the patient. The test is relatively
impervious to data non-stationarities and artifacts, setting it apart from
other measures with unparalleled sensitivity.

A large physician shareholder base represents the early adoptees of
this Company.

Vicor’s PD2i™ Nonlinear Algorithm is:

• A new vital sign with the ability to actually save lives in both
  combat and civilian setting
• The PD2i Analyzer™ can capture and display Heart Rate
  Variability (see defined below) in patients at rest and during paced
  respiration and controlled exercise.
• Able to identify trauma victims in need of an immediate lifesaving
  intervention
• Able to be used along with other clinical data to identify patients at
  risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients
  who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the
  battlefield where time is of the essence and the collection of
  ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one
  to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG
  data
• Functional in trauma environments and battlefield situations

READ THE FULL STOCKGURU PROFILE HERE:

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=947&F=H">http://www.stockguru.com/about/vicor/

Live
Twitter Alerts All Market Day

Our
Twitter Feed includes all live posts from StockGuru.com.

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=141&F=H"> src="http://www.stockguru.com/l/twitter-163w.gif" border="0" />

Featured
on StockGuru

While
we cover many companies, here are our current featured profiles
on StockGuru:

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1086&F=H"
style="color: #576164">Halo Companies, Inc..
(OTCBB:
GPAX)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=980&F=H"
style="color: #576164">Diagnostic Imaging
International Corp.
(OTCBB: DIIG)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=947&F=H"
style="color: #576164">Vicor Technologies, Inc.
(OTCBB:
VCRT)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1094&F=H"
style="color: #576164">Medizone International
(OTCBB: MZEI)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1093&F=H"
style="color: #576164">Skinvisible, Inc.
(OTCBB: SKVI)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=36&F=H"
style="color: #576164">Muscle Flex, Inc.
(OTCBB: MFLI)

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=666&F=H"> src="http://www.boldstocks.com/images/BOLD-163-178.gif" border="0"
height="178" width="163" />

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=3&F=H"
style="color: #576164"> href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=204&F=H"> src="http://www.stockguru.com/l/china/china-163-wide.gif" border="0"
height="155" width="163" />

href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=1&F=H"
style="color: #576164">

StockGuru
Spotlight Alerts

Here
are our latest Spotlight Alerts. Note that we typically
do NOT email these to members. You must visit the site at href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=4&F=H"
style="color: #576164">THIS LINK to keep up to
date; or you may subscribe to href="http://www.sgurunews.com/emailmarketer/link.php?M=16735&N=638&L=2&F=H"
style="color: #576164">THIS RSS
FEED.

Suggest
a Client:

Do you
know a great company that simply must be featured on
StockGuru or Shareholder Vision?

Suggest it
to us.

Email: href="mailto:john@stockguru.com" style="color:
#576164">john@stockguru.com
Tel: (469) 252-3031.